Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer

Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age